A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE

Analytical Pharmacology

Analytical Pharmacology Core Facility (APCF)
The Analytical Pharmacology Core facility (APCF) encourages and facilitiates collaborative research between basic scientists and clinicians by providing a wide range of analytical services that benefit both groups. The APCF conducts pharmacokinetic and pharmacodynamic studies for both chemotherapy clinical trials and peer-reviewed preclinical studies.
 
The primary services of the APCF are:
 
  • Assay development and analysis (LS/MS/MS, GC/MS, HPLC, and AAS) of chemotherapeutic agents and related compounds.
  • Study design and expert analysis of pharmacokinetic, pharmacodynamic, and metabolic data.
 
The facility’s services are available to both City of Hope and external researchers.
 

Research reported in this publication included work performed in the Analytical Pharmacology Core supported by the National Cancer Institute of the National Institutes of Health under award number P30CA33572. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
 

 

Contact Us

Edward Newman, Ph.D.
Co-director
626-256-HOPE (4673)
enewman@coh.org
 
Timothy W. Synold, Pharm.D.
Co-director
626-256-HOPE (4673)
tsynold@coh.org
 
City of Hope and Beckman Research Institute
1500 East Duarte Road
Duarte, CA  91010-3000
 
Shapiro Building
Room 1042
Phone: 626-256-HOPE (4673), ext. 62110
Fax: 626-301-8898
 

Using the Facility

Scheduling Equipment
To access the Analytical Pharmacology Core facility, investigators should contactTimothy Synoldto start the process.

Services and Equipment

Services
Services currently offered by the Analytical Pharmacology Core facility:
  • Initial consultation on research projects
  • Study design and protocol review
  • Development, implementation, and validation of analytical methods.
  • Sample analysis (LC/MS/MS, GC/MS, HPLC, and AAS).
  • Pharmacokinetic programming and data analysis
  • Sample acquisition, tracking, and storage. Sample acquisition, storage analysis, including HPLC, LC/MS/MS and GC/MS, and microbiological assay methodologies
  • Participation in collaborative writing

Equipment
Analytical capabilities cover a wide range of available methods including:
  • LC/MC/MS (Waters Quattro Ultima and Quattro Premier XE
  • GC/MS (2 Shimadzu QP-5000's
  • HPLC with UV/Vis, fluorescence, and electrochemical detection (Shimadzu and Thermo Separations)
  • AAS with graphite furnace (PerkinElmer AAnalyst 300

HPLC capability includes four complete systems, which are integrated directly to dedicated computers running EZChrom software for automated post-run analysis. Three of the HPLC systems include automated injection systems for more convenient analysis of a large number of samples.

Instrument control and data acquisition for the Micromass mass detector and the associated Agilent HPLC are coordinated through a MassLynx-NT workstation running MassLynx and QuanLynx software. The GC/MS instrumentation is composed of a Shimadzu Model QP-5000 EI gas chromatograph/mass spectrometer, interfaced directly to a dedicated computer running CLASS-5000 software.

In addition to the chromatographic instrumentation, a Perkin Elmer AAnalyst 300 flameless atomic absorption spectrometer (AA) is available for the determination of metals and metal-containing compounds such as cisplatin and its analogs. Sample analysis by AA utilizes an automated injection system, with data acquisition and analysis using WinLab software on a dedicated computer.

 

Abstract for Grants

The APCF is located in the Shapiro Building and the analytical equipment is in room 1042. Freezers for sample storage are also located in the Beckman Center Freezer Farm, Room 1012. An additional HPLC with a diode array detector that is used part time for core service activities is located in room 1002 of the Fox North Research Building. HPLC capability includes four complete HPLC systems consisting of seven solvent delivery modules (4 Shimadzu LC-10A's, 2 Shimadzu LC-10AD's, 1 SpectraSystem P4000). HPLC detection capabilities cover a wide range of currently available methods, including UV/Vis (Shimadzu SPD-10AV), fluorescence (Shimadzu RF-10A), electrochemical (ESA models 5100A and 5200A), and photodiode array (SpectraSystem UV6000LP) detection systems. The Shimadzu HPLC systems are integrated directly into one of two dedicated PC's running Shimadzu EZChrom software for automated post-run analysis. Likewise, the SpectraSystem system is integrated to a dedicated PC running Chromquest (OEM version of EZChrom software). Three of the four HPLC systems include automated injection systems (2 Shimadzu SIL-10A's, 1 SpectraSystem AS3000) for more convenient analysis of a large number of samples. A Perkin Elmer AAnalyst 300 AA is available for the determination of metals and metal containing compounds, such as cisplatin and its analogs. Sample analysis by AA utilizes an automated injection system, with data acquisition and analysis using WinLab software on a dedicated PC. The GC/MS instrumentation is composed of a Shimadzu Model QP-5000 EI gas chromatograph/mass spectrometer, interfaced directly to a dedicated PC running CLASS-5000 software. A Micromass Quattro Ultima API Triple Stage Quadrupole Mass Spectrometer System (LC/MS/MS) provides exquisite selectivity and sensitivity for analytes in complex biological matrices. Instrument control and data acquisition for the Micromass mass detector and the associated Agilent HPLC are coordinated through a MassLynx-NT Workstation running MassLynx and QuanLynx software. As a result of high demand for LC/MS/.MS services, a second triple quadrupole tandem mass spectrometer (Waters Premier XE) was recently obtained to increase our capabilities. The front-end on the Premier XE is a Waters Agility Ultra-high Pressure Liquid Chromatograph (UPLC) that allows us to maximize sensitivity and minimize run-times, thereby increasing throughput. Like the Quattro Ultima, instrument control and data analysis on the Premier XE is performed with MassLynx and QuanLynx software. In addition, MetaboLynx software was purchased to aid in metabolite identification.

Analytical Pharmacology Team

Research Shared Services

City of Hope embodies the spirit of scientific collaboration by sharing services and core facilities with colleagues here and around the world.
 

Recognized nationwide for its innovative biomedical research, City of Hope's Beckman Research Institute is home to some of the most tenacious and creative minds in science.
City of Hope is one of only 41 Comprehensive Cancer Centers in the country, the highest designation awarded by the National Cancer Institute to institutions that lead the way in cancer research, treatment, prevention and professional education.
Learn more about City of Hope's institutional distinctions, breakthrough innovations and collaborations.
Support Our Research
By giving to City of Hope, you support breakthrough discoveries in laboratory research that translate into lifesaving treatments for patients with cancer and other serious diseases.
 
 
 
 
Media Inquiries/Social Media

For media inquiries contact:

Dominique Grignetti
800-888-5323
dgrignetti@coh.org

 

For sponsorships inquiries please contact:

Stefanie Sprester
213-241-7160
ssprester@coh.org

Christine Nassr
213-241-7112
cnassr@coh.org

 
CONNECT WITH US
Facebook  Twitter  YouTube  Blog
 
NEWS & UPDATES
  • Eleven years ago, lymphoma patient Christine Pechera began the long road toward a cancer-free life. She had been diagnosed with non-Hodgkin lymphoma and told by doctors elsewhere that her lifespan likely would be measured in months, not years. Refusing to give up, she came to City of Hope for a second opinion. ...
  • Brain surgery is not for the faint of heart. It takes courage, as well as curiosity and compassion. The truly great surgeons also have a desire to find new, and better ways, of healing the brain. Enter Behnam Badie, M.D., chief of neurosurgery at City of Hope. Now a pioneer in brain tumor treatment, Badie enter...
  • Elizabeth Budde, M.D., Ph.D., wants to encourage infighting. She aims to turn the immune system on itself — to the benefit of patients with acute myeloid leukemia, or AML. AML arises when abnormal white blood cells grow out of control, amassing in the bone marrow and interfering with normal blood cell developme...
  • Six, to date; more soon. Outpatient bone marrow transplants, that is. Finding new ways to deliver quality care with the greatest benefit is a priority for a patient-centered institution like City of Hope. For example, not every bone marrow transplant patient needs to check into the hospital for treatment. In fa...
  • The best measure of success in the fight against cancer is in lives saved and families intact, in extra days made special simply because they exist. Yuman Fong, M.D., chair of the Department of Surgery at City of Hope, understands what precedes that special awareness. When cancer strikes, one minute a person ma...
  • In cancer, expertise matters. So do survival rates, patient safety, patient services and many other factors. City of Hope understands this, as does U.S.News & World Report. The magazine’s 2014-2015 list of best hospitals for cancer once again includes City of Hope, ranking the institution 12 out of 900 elig...
  • At 29, Kommah McDowell was a successful young professional engaged to be married to her best friend. She worked in the financial services sector and kick-boxed to keep in shape and to relax. Then came the diagnosis of triple-negative inflammatory breast cancer, a rare and very aggressive form of breast cancer. ...
  • The well-known drug tamoxifen might not always be the best choice for premenopausal women who have undergone treatment for breast cancer and face a heightened risk of recurrence. A new study suggests that the aromatase inhibitor exemestane, or Aromasin, works slightly better than tamoxifen in preventing cancer ...
  • At age 44, Bridget Hanchette, a mother of three from La Crosse, Wisconsin, was diagnosed with grade IV glioblastoma, the most aggressive type of malignant brain tumor. The cancer grows and spreads quickly, making it difficult to treat. Most patients with this diagnosis are not given much hope, but Hanchette’s i...
  • Survival rates for childhood cancer have improved tremendously over the past few decades, but postcancer care hasn’t always kept up. More children than ever are now coping with long-term complications and side effects caused by their disease and treatment — one of those being learning difficulties. A new ...
  • When Sheldon Querido, a retired manufacturer’s representative, was diagnosed with bladder cancer, his doctor told him that he’d need to have his bladder removed – and that he’d have to wear an external urine-collection bag for the rest of his life. “My first response was ‘I donR...
  • To stop smoking, two approaches might be better than one. A new study has found that using the medication varenicline, or Chantix – along with nicotine patches – was more effective than the medicine alone in helping people quit. The study, conducted by Stellanbosch University in Cape Town, South Africa, and pub...
  • John Cloer was three months shy of his third birthday in 2004 when he was diagnosed with acute lymphoblastic leukemia. For the next three and a half years, he received chemotherapy at City of Hope, finally obtaining long-term remission. His parents Bill and Gina, along with John and his younger brother Steve, r...
  • News about the risks or benefits of widespread cancer screening seem to arrive daily – 3D mammography for breast cancer, CT scans for lung cancer, PSA tests for prostate cancer and now pelvic exams for some women’s cancers. Missing in the headlines is a reflection of how cancer detection is evolving. Today’s ca...
  • Adults with sickle cell disease soon may have a new treatment option: bone marrow transplants. Children with sickle cell disease have been treated successfully with transplantation of bone marrow, more officially known as hematopoietic stem cells, from other people. But the procedure has been less successful in...